- Home
- BLNK vs ACTU Comparison
BLNK vs ACTU Comparison
Compare BLNK & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ACTU
- Stock Information
- Founded
- BLNK 2009
- ACTU 2015
- Country
- BLNK United States
- ACTU United States
- Employees
- BLNK N/A
- ACTU N/A
- Industry
- BLNK Industrial Specialties
- ACTU
- Sector
- BLNK Consumer Discretionary
- ACTU
- Exchange
- BLNK Nasdaq
- ACTU NYSE
- Market Cap
- BLNK 163.4M
- ACTU 162.1M
- IPO Year
- BLNK N/A
- ACTU 2024
- Fundamental
- Price
- BLNK $1.39
- ACTU $9.45
- Analyst Decision
- BLNK Buy
- ACTU
- Analyst Count
- BLNK 7
- ACTU 0
- Target Price
- BLNK $5.92
- ACTU N/A
- AVG Volume (30 Days)
- BLNK 4.7M
- ACTU 47.8K
- Earning Date
- BLNK 03-13-2025
- ACTU 02-21-2025
- Dividend Yield
- BLNK N/A
- ACTU N/A
- EPS Growth
- BLNK N/A
- ACTU N/A
- EPS
- BLNK N/A
- ACTU N/A
- Revenue
- BLNK $138,728,000.00
- ACTU N/A
- Revenue This Year
- BLNK N/A
- ACTU N/A
- Revenue Next Year
- BLNK $22.16
- ACTU N/A
- P/E Ratio
- BLNK N/A
- ACTU N/A
- Revenue Growth
- BLNK 15.13
- ACTU N/A
- 52 Week Low
- BLNK $1.31
- ACTU $5.51
- 52 Week High
- BLNK $3.75
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- BLNK 38.51
- ACTU N/A
- Support Level
- BLNK $1.41
- ACTU N/A
- Resistance Level
- BLNK $1.51
- ACTU N/A
- Average True Range (ATR)
- BLNK 0.11
- ACTU 0.00
- MACD
- BLNK -0.01
- ACTU 0.00
- Stochastic Oscillator
- BLNK 15.69
- ACTU 0.00
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.